Peter E Westerweel

25PUBLICATIONS
74CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Rehabilitation engineeringPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (25)

|Nov 18, 2025
Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint.

Fausto Castagnetti, Massimo Breccia, Elisabetta Abruzzese

|Feb 17, 2025
Treatment-Free Remission Outcomes in a BCR::ABL1 Digital PCR Selected Clinical Cohort of CML Patients.

C Kockerols, P J M Valk, P Hogenbirk

|Jan 10, 2025
Sustained treatment-free remission in two chronic myeloid leukemia patients after asciminib discontinuation: a report of two cases.

Arjen Yousefi, Mark-David Levin, Jan J Cornelissen

|Jan 06, 2025
Treatment with obinutuzumab plus venetoclax reshapes the TRB repertoire of CLL patients.

Paul J Hengeveld, Joyce Schilperoord-Vermeulen, P Martijn Kolijn

|Aug 11, 2024
Varying concentrations of tyrosine kinase inhibitors in chronic myeloid leukemia patients following bariatric surgery: a case series.

Cedric Lau, Charlotte van Kesteren, Yong Xin Cao

|Jul 12, 2024
Prediction of sustained remission after tyrosine kinase inhibitor discontinuation with BCR::ABL1 digital PCR in chronic myeloid leukemia patients.

Camille Kockerols, Peter J M Valk, Jeroen J W M Janssen

Pageof 5

Frequent Collaborators

8 joint publications

Mark-David Levin

6 joint publications

Paul J Hengeveld

5 joint publications

Anton W Langerak

4 joint publications

Geneviève Icg Ector